Subclinical hypothyroidism and trying to conceive

What does subclinical hypothyroidism actually mean?

Subclinical hypothyroidism means your TSH level is above the normal upper limit while your free T4 is still within the normal range. In plain terms: your pituitary gland is sending out more thyroid-stimulating hormone (TSH) than usual, as if it's working a bit harder to keep things running. But your actual thyroid hormone output (free T4) hasn't dropped below normal yet. It's an early, milder pattern, not a full thyroid hormone shortage.

It's also more common than many people realize. Estimates put it at somewhere between 3% and 15% of the population, depending on which group is studied. And because it's a mild form of the condition, it often causes no clear symptoms at all. Some women with it may not need treatment. That mix of "common" and "often silent" is exactly why it can be confusing to know whether it's worth acting on.

Where does "normal" end, and why does the cutoff matter?

One reason this topic feels murky is that "normal" isn't one fixed number. When there's no age-based reference range available, ASRM's guideline sets the upper limit of normal TSH at 4.12 mIU/L for diagnosing subclinical hypothyroidism. A result just above that line technically counts. But how serious it is still varies a lot from there.

Cleveland Clinic grades subclinical hypothyroidism by TSH level. Grade 1 spans a TSH of 4.5 to 9.9 mIU/L. Grade 2 is a TSH of 10 mIU/L or higher. In other words, a TSH of 5 and a TSH of 12 are both technically "subclinical." But they're not the same situation, and your provider likely won't approach them the same way.

Who actually needs to be tested?

It might seem logical to test everyone's thyroid the moment they start trying to conceive. But that's not what current guidance recommends. ASRM recommends checking TSH and T4 in patients who have signs or symptoms of low thyroid function, including irregular periods. It does not recommend testing every patient being evaluated for fertility. So thyroid testing tends to be targeted, based on your history and symptoms, rather than a blanket check applied to everyone with a regular cycle and no red flags.

The same targeted approach applies to thyroid antibody testing. ASRM does not recommend routinely screening people with no symptoms, whether trying to conceive or already pregnant, for thyroid antibodies. Targeted screening can still be considered for women with a history of repeated pregnancy loss. If your provider hasn't ordered antibody testing and you don't have that history, that's consistent with current guidance, not an oversight.

Should a mildly high TSH be treated?

This is where the nuance really lives. It helps to separate two different questions: does treatment help, and does the number sometimes fix itself. On the first question, ASRM's guideline does not recommend treating subclinical hypothyroidism with thyroid medication (levothyroxine) in women who are trying to conceive or already pregnant. That treatment hasn't been proven to reduce pregnancy loss or improve the chances of a live birth. That's a meaningful, evidence-based statement. Not every unusual-looking lab result needs a prescription to fix it.

On the second question, timing matters. For patients with a TSH under 10 mIU/L and a normal free T4, guidance calls for repeating the blood work in 3 to 6 months before starting treatment. This is because nearly half of these cases return to normal on their own. That's a striking number. Close to half the time, a mildly high TSH normalizes without any treatment at all. That's why watching and retesting is often the first, most reasonable step rather than jumping to medication.

There is one important exception worth knowing. For pregnant patients, or those planning pregnancy, who have mild thyroid changes, thyroid medication is advised. This is particularly true when thyroid peroxidase antibodies (TPOAb, an immune marker linked to thyroid problems) test positive. That combination carries a higher risk of worse outcomes for the pregnancy and baby. So antibody status can change the plan even when the TSH itself is only mildly high.

Is the target different if you're doing IVF?

If you're going through IVF or ICSI (a type of IVF where a single sperm is injected directly into an egg), the guidance you'll hear may sound different from what applies to conceiving naturally. That's intentional, not a contradiction. For women with subclinical hypothyroidism undergoing IVF or ICSI, the American Thyroid Association recommends thyroid medication aimed at bringing TSH down to 2.5 mIU/L. That's a notably lower target than the general diagnostic cutoff.

This is a good reason to ask your provider directly which set of guidelines applies to your situation. A TSH of 5 mIU/L might call for a "let's recheck in a few months" conversation if you're trying to conceive naturally. It might call for a more active approach if you're partway through an IVF cycle.

What should you do with your own results?

If you've seen a TSH result that's slightly above range with a normal free T4, the most evidence-based response is usually not panic and not dismissal. It's context. Ask what your specific number is, and whether it falls into grade 1 or grade 2 territory. Ask whether your free T4 and antibody status have been checked. Ask whether repeat testing in a few months makes sense before any treatment decision, and whether your path to conceiving (natural conception versus IVF/ICSI) changes the recommended target.

"Normal" on a lab report covers a wide range. Where you fall within it, combined with your symptoms, your antibody status, and your specific path to conceiving, is what actually shapes the right next step. That's a conversation worth having with your provider directly, based on the specifics of your own labs rather than a single number on its own.

Frequently asked questions

Sources

1. Subclinical hypothyroidism is defined as a TSH level above the normal upper limit while free T4 remains within the normal range. — ASRM
2. When no age-based reference range is available, ASRM's guideline sets the upper limit of normal TSH at 4.12 mIU/L for diagnosing subclinical hypothyroidism. — ASRM
3. ASRM's guideline does not recommend treating subclinical hypothyroidism with levothyroxine in women who are trying to conceive or already pregnant, because such treatment has not been proven to reduce pregnancy loss or improve live birth outcomes. — ASRM
4. ASRM recommends checking TSH and T4 in patients who have signs or symptoms of hypothyroidism, including irregular menstrual cycles, rather than testing every patient being evaluated for infertility. — ASRM
5. ASRM does not recommend routinely screening asymptomatic infertility or pregnant patients for thyroid autoimmunity (antibodies), though targeted screening can be considered in women with a history of recurrent pregnancy loss. — ASRM
6. The estimated prevalence of subclinical hypothyroidism ranges from 3% to 15% of the population depending on which group is studied. — StatPearls/NCBI
7. For pregnant patients (or those planning pregnancy) with mild thyroid dysfunction, levothyroxine treatment is advised, particularly when thyroid peroxidase antibodies (TPOAb) are positive, since this combination carries a higher risk of worse pregnancy and fetal outcomes. — StatPearls/NCBI
8. For patients with a TSH under 10 mIU/L and a normal free T4, guidance calls for repeating the thyroid blood work in 3 to 6 months before starting treatment, since nearly half of these cases resolve on their own. — StatPearls/NCBI
9. For women with subclinical hypothyroidism undergoing IVF or ICSI, the American Thyroid Association's recommendation (as summarized by Cleveland Clinic) is levothyroxine treatment aimed at bringing TSH down to 2.5 mIU/L. — Cleveland Clinic
10. Subclinical hypothyroidism is graded by TSH level: grade 1 spans TSH of 4.5 to 9.9 mIU/L, while grade 2 is TSH of 10 mIU/L or higher. — Cleveland Clinic
11. Subclinical hypothyroidism is a mild form of the disease that often produces no clear symptoms, and some women with it may not need treatment. — NIDDK/NIH